Hormone therapy regimens for managing the menopause and premature ovarian insufficiency

Armeni, Eleni; Paschou, Stavroula Α.; Goulis, Dimitrios G.; Lambrinoudaki, Ιrene

doi:10.1016/j.beem.2021.101561

Cited by 60 publications

(32 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic MHT also reduces the risk of osteoporotic fracture during treatment but antifracture efficacy decreases once treatment is stopped [4]. Women who experience premature menopause are recommended to take MHT until their early 50 s, not only to treat symptoms but also to reduce the risk of osteoporosis and cardiovascular disease [34]. Thereafter it should be reassessed.…”

Section: Duration Of Usementioning

confidence: 99%

The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction:The menopause, or the cessation of menstruation, is a stage of the life cycle which will occur in all women. Managing perimenopausal and postmenopausal health is a key issue for all areas of healthcare, not just gynecology. Aim: To provide recommendations for the curriculum of education programs for healthcare professionals worldwide, so that all can receive high quality training on menopause. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: Training programs for healthcare professionals worldwide should include menopause and postmenopausal health in their curriculum. It should include assessment, diagnosis and evidence-based management strategies.

show abstract

Section: Duration Of Usementioning

confidence: 99%

The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Consequently, women with POI suffer from subfertility and are susceptible to estrogen deficiency‐related aging symptoms in the bone, cardiovascular system, and central nervous system (Tsiligiannis et al , 2019 ; Samad et al , 2020 ; Stevenson et al , 2021 ). Hormone replacement therapy (HRT) can certainly alleviate these symptoms (Luisi et al , 2015 ; Webber et al , 2017 ; Armeni et al , 2021 ), though the therapies to prevent or cure POI itself are still absent.…”

Section: Introductionmentioning

confidence: 99%

BCAA insufficiency leads to premature ovarian insufficiency via ceramide‐induced elevation of ROS

Guo

Zhu

et al. 2023

EMBO Mol Med

View full text Add to dashboard Cite

Premature ovarian insufficiency (POI) is a disease featured by early menopause before 40 years of age, accompanied by an elevation of follicle‐stimulating hormone. Though POI affects many aspects of women's health, its major causes remain unknown. Many clinical studies have shown that POI patients are generally underweight, indicating a potential correlation between POI and metabolic disorders. To understand the pathogenesis of POI, we performed metabolomics analysis on serum and identified branch‐chain amino acid (BCAA) insufficiency‐related metabolic disorders in two independent cohorts from two clinics. A low BCAA diet phenotypically reproduced the metabolic, endocrine, ovarian, and reproductive changes of POI in young C57BL/6J mice. A mechanism study revealed that the BCAA insufficiency‐induced POI is associated with abnormal activation of the ceramide‐reactive oxygen species (ROS) axis and consequent impairment of ovarian granulosa cell function. Significantly, the dietary supplement of BCAA prevented the development of ROS‐induced POI in female mice. The results of this pathogenic study will lead to the development of specific therapies for POI.

show abstract

“…Studying POI as a vaccine adverse event is challenging for many reasons. The most important relies on the fact that the time from symptom onset to diagnosis with POI may be variable or long [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence

et al. 2023

View full text Add to dashboard Cite

(1) Background: Premature ovarian insufficiency (POI) has been linked to human papilloma virus (HPV) vaccination in small case-reports. The aim of this meta-analysis was to evaluate the risk of POI after HPV vaccination. (2) Methods: Electronic searches in MEDLINE Scopus, LILACS, ClinicalTrials.gov, EMBASE, PROSPERO, Cochrane CENTRAL and other registries were searched from inception to September 2022. Inclusion criteria were cohort studies of female children or adolescents vaccinated with quadrivalent (4vHPV), bivalent (2vHPV) or 9-valent (9vHPV) vaccine and compared to unvaccinated, other HPV vaccine, or vaccinated with other childhood vaccine girls. Primary outcome was risk of POI after vaccination. (3) Results: Four studies, including 1,253,758 patients, were included. Overall, there was no significant risk for POI between 4vHPV and controls (unvaccinated or other vaccines) (RR 0.47 (95% CI 0.14 to 1.59) I2 = 75%), or unvaccinated only controls (RR 0.75 (95% CI 0.22 to 2.49) I2 = 26%). One study reported a significant reduction of POI risk for 4vHPV relative to the other childhood vaccinations (RR 0.03 (95% CI 0.00 to 0.21)); meanwhile, one study showed no increased risk with 4vHPV relative to 2vHPV and 9vHPV (RR 0.93 (95% CI 0.33 to 2.64)). (4) Conclusions: 4vHPV vaccination does not seem to increase risk of POI relative to unvaccinated people or other childhood vaccines. No difference was seen with 4vHPV vaccine relative to 2vHPV and 9vHPV. Moreover, the risk of POI after HPV vaccination is relatable to worldwide incidence, giving reassurance about safety.

show abstract

Hormone therapy regimens for managing the menopause and premature ovarian insufficiency

Cited by 60 publications

References 43 publications

The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement

The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement

BCAA insufficiency leads to premature ovarian insufficiency via ceramide‐induced elevation of ROS

Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence

Contact Info

Product

Resources

About